Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03733301
Registration number
NCT03733301
Ethics application status
Date submitted
30/10/2018
Date registered
7/11/2018
Titles & IDs
Public title
A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7
Query!
Secondary ID [1]
0
0
I4V-MC-JAIY
Query!
Secondary ID [2]
0
0
17100
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BREEZE-AD7
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Baricitinib
Treatment: Drugs - Topical corticosteroid
Treatment: Drugs - Placebo
Experimental: 4 Milligram (mg) Baricitinib - 4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.
Experimental: 2 mg Baricitinib - 2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.
Placebo comparator: Placebo - Placebo administered orally once daily in combination with TCS.
Treatment: Drugs: Baricitinib
Administered orally.
Treatment: Drugs: Topical corticosteroid
Administered as standard-of-care.
Treatment: Drugs: Placebo
Administered orally.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a = 2 Point Improvement
Query!
Assessment method [1]
0
0
The IGA measures investigators global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)
Query!
Assessment method [1]
0
0
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI75 is defined as a = 75% improvement from baseline in the EASI score.
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving EASI90
Query!
Assessment method [2]
0
0
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI90 is defined as a = 90% improvement from baseline in the EASI score.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [3]
0
0
Percent Change From Baseline on EASI Score
Query!
Assessment method [3]
0
0
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe).
Least Squares Mean (LSM) were calculated using mixed model repeated measures (MMRM) with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit interaction as fixed categorical effects and baseline score and baseline score-by-visit interaction as fixed continuous effects.
Query!
Timepoint [3]
0
0
Baseline, Week 16
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)
Query!
Assessment method [4]
0
0
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD75 responder is defined as a participant who achieves a = 75% improvement from baseline in the SCORAD score.
Query!
Timepoint [4]
0
0
Week 16
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS)
Query!
Assessment method [5]
0
0
The Itch NRS is a patient-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.
Query!
Timepoint [5]
0
0
Week 16
Query!
Secondary outcome [6]
0
0
Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)
Query!
Assessment method [6]
0
0
The ADSS is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep due to itch, frequency of waking due to itch, and difficulty getting back to sleep last night due to itch. Item 2 frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep "last night." Each item is scored individually. LS Mean were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit interaction as fixed categorical effects and baseline score and baseline score-by-visit interaction as fixed continuous effects.
Query!
Timepoint [6]
0
0
Baseline, Week 16
Query!
Secondary outcome [7]
0
0
Change From Baseline in Skin Pain NRS
Query!
Assessment method [7]
0
0
Skin Pain NRS is a patient-administered,11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable." Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours. LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.
Query!
Timepoint [7]
0
0
Baseline, Week 16
Query!
Secondary outcome [8]
0
0
Percentage of Participants Achieving EASI50
Query!
Assessment method [8]
0
0
The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72 (severe). The EASI50 is defined as a = 50% improvement from baseline in the EASI score.
Query!
Timepoint [8]
0
0
Week 16
Query!
Secondary outcome [9]
0
0
Percentage of Participants Achieving IGA of 0
Query!
Assessment method [9]
0
0
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Query!
Timepoint [9]
0
0
Week 16
Query!
Secondary outcome [10]
0
0
Change From Baseline in SCORAD
Query!
Assessment method [10]
0
0
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.
LS Means were calculated using a MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by- visit-interaction as fixed continuous effects.
Query!
Timepoint [10]
0
0
Baseline, Week 16
Query!
Secondary outcome [11]
0
0
Percentage of Participants Achieving SCORAD90
Query!
Assessment method [11]
0
0
The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease: (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD90 is defined as a = 90% improvement from baseline in the SCORAD score.
Query!
Timepoint [11]
0
0
Week 16
Query!
Secondary outcome [12]
0
0
Change From Baseline in Body Surface Area (BSA) Affected
Query!
Assessment method [12]
0
0
The BSA affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs.
LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [12]
0
0
Baseline, Week 16
Query!
Secondary outcome [13]
0
0
Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment
Query!
Assessment method [13]
0
0
Percentage of participants developing skin infections requiring antibiotic treatment.
Query!
Timepoint [13]
0
0
Week 16
Query!
Secondary outcome [14]
0
0
Mean Gram Quantity of Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights)
Query!
Assessment method [14]
0
0
Average weights of full tubes were used to determine the dispensed weights for each region. Returned tubes were weighed with cap without carton to determine the amount of TCS in grams (g) used at each visit. Analysis was done via analysis of variance (ANOVA), with geographic region, baseline disease severity (IGA) and treatment as factors in the model.
Query!
Timepoint [14]
0
0
Week 0 through Week 16
Query!
Secondary outcome [15]
0
0
Percent Change From Baseline in Itch NRS
Query!
Assessment method [15]
0
0
The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.
LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects.
Query!
Timepoint [15]
0
0
Baseline, Week 16
Query!
Secondary outcome [16]
0
0
Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)
Query!
Assessment method [16]
0
0
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life.
LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [16]
0
0
Baseline, Week 16
Query!
Secondary outcome [17]
0
0
Change From Baseline in the Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score
Query!
Assessment method [17]
0
0
The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are "(0) no symptoms", "(1) very mild", "(2) mild" "(3) moderate", and "(4) severe."
LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [17]
0
0
Baseline, Week 16
Query!
Secondary outcome [18]
0
0
Change From Baseline on the Hospital Anxiety Depression Scale (HADS)
Query!
Assessment method [18]
0
0
The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.'
LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [18]
0
0
Baseline, Week 16
Query!
Secondary outcome [19]
0
0
Change From Baseline on the Dermatology Life Quality Index (DLQI)
Query!
Assessment method [19]
0
0
The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and at unanswered ("not relevant") responses scored as "0." Scores range from 0 to 30 (less to more impairment), and a 4-point change from baseline is considered as the minimal clinically important difference threshold.
LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [19]
0
0
Baseline, Week 16
Query!
Secondary outcome [20]
0
0
Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire
Query!
Assessment method [20]
0
0
The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment.
LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [20]
0
0
Baseline, Week 16
Query!
Secondary outcome [21]
0
0
Change From Baseline on the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm
Query!
Assessment method [21]
0
0
The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state.
LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [21]
0
0
Baseline, Week 16
Query!
Secondary outcome [22]
0
0
Change From Baseline on the EQ-5D-5L Visual Analog Scale (VAS)
Query!
Assessment method [22]
0
0
The EQ-5D-5L is a 2-part measurement. The second part is assessed using a VAS that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.
LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects.
Query!
Timepoint [22]
0
0
Baseline, Week 16
Query!
Secondary outcome [23]
0
0
Mean Number of Days Without Use of Background TCS
Query!
Assessment method [23]
0
0
The ANCOVA model includes treatment, region, and baseline disease severity (IGA) as factors.
Query!
Timepoint [23]
0
0
Week 0 through Week 16
Query!
Secondary outcome [24]
0
0
Percentage of Participants Achieving IGA of 0 or 1 With a = 2 Point Improvement
Query!
Assessment method [24]
0
0
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Query!
Timepoint [24]
0
0
Week 4
Query!
Eligibility
Key inclusion criteria
* Have been diagnosed with moderate to severe atopic dermatitis for at least 12 months.
* Have had inadequate response to existing topical (applied to the skin) medications within 6 months preceding screening.
* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).
* Agree to use emollients daily.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.
* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past.
* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
* Have been treated with the following therapies:
* Monoclonal antibody for less than 5 half-lives prior to randomization.
* Received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks prior to randomization.
* Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
* Have had an intra-articular corticosteroid injection within 6 weeks prior to planned randomization.
* Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.
* Have had major surgery within the past eight weeks or are planning major surgery during the study.
* Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
* Have a history of recurrent (=2) VTE or are considered at high risk of VTE as deemed by the investigator.
* Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
* Have specific laboratory abnormalities.
* Have received certain treatments that are contraindicated.
* Pregnant or breastfeeding.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/11/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/08/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
329
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Woden Dermatology - Phillip
Query!
Recruitment hospital [2]
0
0
Skin & Cancer Foundation Australia - Westmead
Query!
Recruitment hospital [3]
0
0
The Skin Centre - Benowa
Query!
Recruitment hospital [4]
0
0
Veracity Clinical Research Pty Ltd - Woolloongabba
Query!
Recruitment hospital [5]
0
0
Clinical Trials SA Pty Ltd - Adelaide
Query!
Recruitment hospital [6]
0
0
Skin and Cancer Foundation Inc. - Melbourne
Query!
Recruitment hospital [7]
0
0
Fremantle Dermatology - Perth
Query!
Recruitment postcode(s) [1]
0
0
2606 - Phillip
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4217 - Benowa
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
0
0
5073 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
3053 - Melbourne
Query!
Recruitment postcode(s) [7]
0
0
6160 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Mendoza
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Steiermark
Query!
Country [4]
0
0
Germany
Query!
State/province [4]
0
0
Baden-Württemberg
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Bayern
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Hessen
Query!
Country [7]
0
0
Germany
Query!
State/province [7]
0
0
Niedersachsen
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Nordrhein-Westfalen
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Schleswig-Holstein
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Berlin
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Hamburg
Query!
Country [12]
0
0
Italy
Query!
State/province [12]
0
0
Lazio
Query!
Country [13]
0
0
Italy
Query!
State/province [13]
0
0
Milano
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Genova
Query!
Country [15]
0
0
Italy
Query!
State/province [15]
0
0
Pisa
Query!
Country [16]
0
0
Italy
Query!
State/province [16]
0
0
Vicenza
Query!
Country [17]
0
0
Japan
Query!
State/province [17]
0
0
Chiba
Query!
Country [18]
0
0
Japan
Query!
State/province [18]
0
0
Fukuoka
Query!
Country [19]
0
0
Japan
Query!
State/province [19]
0
0
Hokkaido
Query!
Country [20]
0
0
Japan
Query!
State/province [20]
0
0
Kanagawa
Query!
Country [21]
0
0
Japan
Query!
State/province [21]
0
0
Osaka
Query!
Country [22]
0
0
Japan
Query!
State/province [22]
0
0
Shizuoka
Query!
Country [23]
0
0
Japan
Query!
State/province [23]
0
0
Tokyo
Query!
Country [24]
0
0
Japan
Query!
State/province [24]
0
0
Toyama
Query!
Country [25]
0
0
Korea, Republic of
Query!
State/province [25]
0
0
Gyeonggi-do
Query!
Country [26]
0
0
Korea, Republic of
Query!
State/province [26]
0
0
Korea
Query!
Country [27]
0
0
Korea, Republic of
Query!
State/province [27]
0
0
Seoul
Query!
Country [28]
0
0
Poland
Query!
State/province [28]
0
0
Lodz
Query!
Country [29]
0
0
Poland
Query!
State/province [29]
0
0
Swidnik
Query!
Country [30]
0
0
Poland
Query!
State/province [30]
0
0
Warszawa
Query!
Country [31]
0
0
Spain
Query!
State/province [31]
0
0
Barcelona
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Cordoba
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Las Palmas de Gran Canaria
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Madrid
Query!
Country [35]
0
0
Taiwan
Query!
State/province [35]
0
0
Kaohsiung
Query!
Country [36]
0
0
Taiwan
Query!
State/province [36]
0
0
New Taipei City
Query!
Country [37]
0
0
Taiwan
Query!
State/province [37]
0
0
Taichung City
Query!
Country [38]
0
0
Taiwan
Query!
State/province [38]
0
0
Taipei City
Query!
Country [39]
0
0
Taiwan
Query!
State/province [39]
0
0
Taipei
Query!
Country [40]
0
0
Taiwan
Query!
State/province [40]
0
0
Taoyuan, (r.o.c.)
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Incyte Corporation
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03733301
Query!
Trial related presentations / publications
Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. Dermatol Ther (Heidelb). 2022 Dec;12(12):2765-2779. doi: 10.1007/s13555-022-00828-5. Epub 2022 Oct 18. Thyssen JP, Buhl T, Fernandez-Penas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Stander S. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7. Dermatol Ther (Heidelb). 2021 Oct;11(5):1599-1611. doi: 10.1007/s13555-021-00577-x. Epub 2021 Jul 18. Buhl T, Rosmarin D, Serra-Baldrich E, Fernandez-Penas P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatol Ther (Heidelb). 2021 Jun;11(3):971-982. doi: 10.1007/s13555-021-00534-8. Epub 2021 Apr 25. King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7. Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, Kolodsick J, Yang FE, Gamalo M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020 Dec 1;156(12):1333-1343. doi: 10.1001/jamadermatol.2020.3260.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Query!
Available to whom?
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/01/NCT03733301/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/01/NCT03733301/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03733301